Oxford Biomedica
Oxford, United Kingdom
Hybrid — also manufactures internal programs
Compare Lentiviral CDMOs in Europe
Compare Lentiviral CDMOs in UK
Compare AAV CDMOs in Europe
Compare AAV CDMOs in UK
Compare Plasmid DNA CDMOs in Europe
Compare Plasmid DNA CDMOs in UK
7 confirmed programs
· 3 sponsors
· Last scored 2026-10-29
76.2
Signal Score
✓ FDA Inspections (2)
✓ Clinical Trials (7)
○ SEC Filings
✓ Press (20)
✓ EMA GMP (4)
✓ MHRA GMP (10)
✓ HC GMP (5)
Quick Facts: Oxford Biomedica
- Signal Score
- 76.2/100 (as of 2026-10-29)
- Quality Compliance
- 100.0/100 — Clean EMA record: 3 active GMP certificates (no deductions)
- Headquarters
- Oxford, United Kingdom
- Website
- https://oxb.com
- Modalities
- Lentiviral, AAV, Plasmid DNA
- Active Programs
- 7 confirmed from ClinicalTrials.gov across 3 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Oxford Biomedica
Pioneer in lentiviral vector manufacturing.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
Clean EMA record: 3 active GMP certificates (no deductions)
Clean MHRA record: 10 compliant GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP, MHRA GMDP
Clean EMA record: 3 active GMP certificates (no deductions) · Clean MHRA record: 10 compliant GMP certificates (no deductions)
FDA Inspections2 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2024-06-17)
EMA GMP Certificates4 on record
MHRA GMP Certificates10 on record
Most Recent HC OutcomeCompliant · 2024-07-23
HC Attribution5 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean EMA record: 3 active GMP certificates (no deductions)
Clean MHRA record: 10 compliant GMP certificates (no deductions)
Operations
58.6
7 active programs across 3 sponsors
Modalities: AAV, Lentiviral, Plasmid DNA
6 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
7 active programs across 3 sponsors · Modalities: AAV, Lentiviral, Plasmid DNA · 6 programs in advanced phases (Phase 2/3)
Programs
7
Sponsors3
ModalitiesLentiviral, AAV, Plasmid DNA
7 active programs across 3 sponsors
Modalities: AAV, Lentiviral, Plasmid DNA
6 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT01856439
Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease
PHASE1/PHASE2
Terminated
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability
75.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
Capacity
58.0
1 manufacturing site: Oxford, UK
Modalities: Lentiviral, AAV, Plasmid DNA
Capacity assessment: 58.0/100
Sites: Oxford, UK
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
StatusAvailable
1 manufacturing site: Oxford, UK
Modalities: Lentiviral, AAV, Plasmid DNA
Capacity assessment: 58.0/100
Sites: Oxford, UK
Press Signals20 articles (not scored)
1 manufacturing site: Oxford, UK
Modalities: Lentiviral, AAV, Plasmid DNA
Capacity assessment: 58.0/100
Oxford Biomedica FDA Inspection History
2024-06
2024-06
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2024-06-17 |
Oxford Biomedica (UK) Limited
Oxford
Company-level
|
Human Cellular, Tissue, and Gene Therapies | Not posted | No Action Indicated (NAI) |
| 2024-06-17 |
Oxford Biomedica (UK) Limited
Kidlington
Company-level
|
Human Cellular, Tissue, and Gene Therapies | Not posted | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
Oxford Biomedica EMA GMP Compliance 4 certificates
2024-04
2023-09
2023-09
2020-12
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| 2024_HPF_FR_112 | Oxford Biomedica (France) S.A.S. | France | 2024-04-12 | COMPLIANT |
| 2024_HPF_FR_026_ND | Oxford Biomedica (France) S.A.S. | France | 2023-09-22 | COMPLIANT |
| 2024_HPF_FR_027_ND | Oxford Biomedica (France) S.A.S. | France | 2023-09-22 | COMPLIANT |
| 30363/IMP12861/001 | OxFord Biomedica (Ireland) Limited | Ireland | 2020-12-15 | NON-COMPLIANT |
Source: EMA EudraGMDP · Retrieved Nov 21, 2026
Oxford Biomedica MHRA GMP Compliance 10 certificates
2026-02
2026-02
2025-07
2025-07
2025-03
2025-03
2024-07
2024-07
2024-07
2024-07
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK MIA 17479 Insp GMP/IMP 17479/19229463-0009[H] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 2ZY | 2026-02-24 | COMPLIANT |
| UK MIA(IMP) 17479 Insp GMP/IMP 17479/19229463-0009[I] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 2ZY | 2026-02-24 | COMPLIANT |
| UK MIA 17479 Insp GMP/IMP 17479/19229463-0008[H] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 2ZY | 2025-07-25 | COMPLIANT |
| UK MIA(IMP) 17479 Insp GMP/IMP 17479/19229463-0008[I] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 2ZY | 2025-07-25 | COMPLIANT |
| UK MIA 17479 Insp GMP/IMP 17479/12357407-0006[H] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX5 1QU | 2025-03-07 | COMPLIANT |
| UK MIA(IMP) 17479 Insp GMP/IMP 17479/12357407-0006[I] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX5 1QU | 2025-03-07 | COMPLIANT |
| UK MIA 17479 Insp GMP/IMP 17479/12551187-0008[H] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 6LT | 2024-07-23 | COMPLIANT |
| UK MIA(IMP) 17479 Insp GMP/IMP 17479/12551187-0008[I] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 6LT | 2024-07-23 | COMPLIANT |
| UK MIA(IMP) 17479 Insp GMP/IMP 17479/285627-0009[I] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 6LX | 2024-07-23 | COMPLIANT |
| UK MIA 17479 Insp GMP/IMP 17479/285627-0009[H] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 6LX | 2024-07-23 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Nov 21, 2026
Clinical Activity 7 studies
NCT01856439
Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease
PHASE1/PHASE2
Terminated
NCT01301443
Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related...
PHASE1
Completed
NCT00627588
Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for...
PHASE1/PHASE2
Completed
NCT00397345
TroVax Renal Immunotherapy Survival Trial
PHASE3
Completed
NCT00445523
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients...
PHASE2
Completed
NCT00325507
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal...
PHASE2
Completed
NCT00083941
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of...
PHASE2
Completed
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Hiring Activity 4 open roles Beta
From public job postings on Oxford Biomedica's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
4
open roles
2
in manufacturing, quality, PD/MSAT, engineering or regulatory (50%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 0 new postings, 0 taken down.
By function
By site
Oxford
profile site
· 2 other 2
· 2 other 2
Bedford, MA
· 1 PD/MSAT 1
· 1 PD/MSAT 1
Durham, NC
· 1 QA/QC 1
· 1 QA/QC 1
Notable roles
Director Quality Control
Senior operations / quality role · Durham, NC
Latest postings
Director Quality Control
Quality (QA / QC) · Durham, NC
Director, UK Revenue & Margin
Other (finance, HR, IT, other) · Oxford
Project Programme Manager 12 month FTC
Commercial, BD & client projects · Oxford
Senior Scientist, Lead Analytical Development Operations
Process development & MSAT · Bedford, MA
Coverage: counted from Oxford Biomedica's own careers board.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
careers.oxb.com
· Checked Nov 20, 2026 · Tracking since Oct 26, 2026
Company Signals 20 articles
Company announcements, not verified evidence. They do not change any score.
Oxford BioMedica Appoints Former Sartorius CEO Joachim Kreuzburg as Non-Executive Director - Yahoo Finance UK
Oxford BioMedica Appoints Former Sartorius CEO Joachim Kreuzburg as Non-Executive Director Yahoo Finance UK
REG - Oxford Biomedica PLC - Appointment of Independent Non-Executive Director - TradingView
REG - Oxford Biomedica PLC - Appointment of Independent Non-Executive Director TradingView
Oxford Biomedica (LSE:OXB) Revenue Growth and Firm Guidance Support Recovery While FTSE 100 Trades Higher - Kalkine Media
Oxford Biomedica (LSE:OXB) Revenue Growth and Firm Guidance Support Recovery While FTSE 100 Trades Higher Kalkine Media
Oxford Biomedica Adds LTIP Shares to London Listing - The Globe and Mail
Oxford Biomedica Adds LTIP Shares to London Listing The Globe and Mail
REG - Oxford Biomedica PLC - Admission to Trading - TradingView
REG - Oxford Biomedica PLC - Admission to Trading TradingView
REG - Oxford Biomedica PLC - Grant of Award - TradingView
REG - Oxford Biomedica PLC - Grant of Award TradingView
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development - The Globe and Mail
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development The Globe and Mail
Oxford Biomedica Launches Fast-track Viral Vector Manufacturing Service - DirectorsTalk Interviews
Oxford Biomedica Launches Fast-track Viral Vector Manufacturing Service DirectorsTalk Interviews
Oxford BioMedica accelerates viral vector development and manufacture - London South East
Oxford BioMedica accelerates viral vector development and manufacture London South East
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development - TipRanks
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development TipRanks
Oxford Biomedica Share News (OXB) - London South East
Oxford Biomedica Share News (OXB) London South East
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role - The Globe and Mail
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role The Globe and Mail
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role - TipRanks
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role TipRanks
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability - Bitget
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability Bitget
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability - Bitget
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability Bitget
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge - ca.investing.com
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge Investing.com Canada
Oxford BioMedica shares fall as warns on loss-making first half - London South East
Oxford BioMedica shares fall as warns on loss-making first half London South East
Earnings call transcript: Oxford Biomedica’s H2 2025 results show strong revenue growth - Investing.com
Earnings call transcript: Oxford Biomedica’s H2 2025 results show strong revenue growth Investing.com
Oxford Biomedica H2 Earnings Call Highlights - Yahoo Finance
Oxford Biomedica H2 Earnings Call Highlights Yahoo Finance
Oxford BioMedica Returns to Profit as U.S. Expansion and Big Pharma Deals Lift Outlook - TipRanks
Oxford BioMedica Returns to Profit as U.S. Expansion and Big Pharma Deals Lift Outlook TipRanks
Frequently Asked Questions About Oxford Biomedica
How many FDA inspections does Oxford Biomedica have on record?
CDMO Signal tracks 2 FDA inspections for Oxford Biomedica, sourced from the FDA inspection database. See the full inspection history above.
Has Oxford Biomedica received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Oxford Biomedica.
Does Oxford Biomedica hold EMA or MHRA GMP certificates?
CDMO Signal tracks 4 EMA and 10 MHRA GMP certificates for Oxford Biomedica.
How many clinical programs is Oxford Biomedica linked to?
Oxford Biomedica is associated with 7 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Oxford Biomedica's CDMO Signal Score?
Oxford Biomedica has a Signal Score of 76/100, based on quality, operations, financial stability, and capacity data.
Evaluating Oxford Biomedica for a manufacturing program?
Use the free AI matchmaker to compare Oxford Biomedica against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 77.6
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid, Small Molecule API, Oral Solid Dose, Sterile Fill-Finish
Andelyn Biosciences
Columbus, OH
Signal Score: 63.0
AAV, Lentiviral, Plasmid DNA
Advent Bioservices
London, United Kingdom
Signal Score: 78.1
AAV, Lentiviral, Adenoviral
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Compare Oxford Biomedica with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.